Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 19/20 | 0.84 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21450534 | 0.94 | TOP1 (0.80) | TOP1SLC2A1 | |
| SCHEMBL21450520 | 0.93 | TOP1 (0.74) | TOP1SLC2A1 | |
| SCHEMBL21450471 | 0.92 | TOP1 (0.72) | TOP1SLC2A1 | |
| SCHEMBL21450330 | 0.91 | TOP1 (0.83) | TOP1SLC2A1 | |
| SCHEMBL21450521 | 0.91 | TOP1 (0.80) | TOP1SLC2A1 | |
| SCHEMBL22230084 | 0.90 | TOP1 (0.87) | TOP1 | |
| SCHEMBL21450562 | 0.90 | TOP1 (0.74) | TOP1SLC2A1 | |
| SCHEMBL21450516 | 0.89 | TOP1 (0.85) | TOP1SLC2A1 | |
| SCHEMBL22598051 | 0.89 | TOP1 (0.67) | TOP1 | |
| SCHEMBL9563408 | 0.88 | TOP1 (0.76) | TOP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | SEAGEN INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC (US) | 2022-06-23 | — | — | US | disclosed |
| US-20190343828-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| WO-2019195665-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPCAM, TOP2A, SPAG5 | TOP1 4/4885SLC2A1 1660/4885 |
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | TOP1 4/4885SLC2A1 3489/4885 |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | TOP1 9/4885SLC2A1 3318/4885 |
| US-20190343828-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | TOP1 9/4885SLC2A1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.